SCHEMBL650810

SCHEMBL650810

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC(C)C)Cc1ccc(OC(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
TSHR P16473 3/20 0.35
LMNA P02545 1/20 0.35
CRHR1 P34998 3/20 0.34
HDAC1 Q13547 1/20 0.34
ATP4A P20648 3/20 0.34
ATP4B P51164 3/20 0.34
ALDH1A1 P00352 2/20 0.33
HTT P42858 1/20 0.33
DRD2 P14416 2/20 0.33
DRD3 P35462 2/20 0.33
DAGLA Q9Y4D2 1/20 0.33
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP3A4 P08684 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
FAAH O00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650283 0.93 C5AR1 (0.42) C5AR1TSHRLMNACRHR1ATP4A
SCHEMBL652236 0.93 C5AR1 (0.42) C5AR1TSHRLMNACRHR1ATP4A
SCHEMBL650201 0.92 C5AR1 (0.41) C5AR1TSHRLMNACRHR1ATP4A
SCHEMBL651033 0.92 C5AR1 (0.44) C5AR1TSHRLMNAATP4AATP4B
SCHEMBL648163 0.91 C5AR1 (0.41) C5AR1TSHRLMNACRHR1ATP4A
SCHEMBL652364 0.91 C5AR1 (0.41) C5AR1TSHRLMNACRHR1ATP4A
SCHEMBL649935 0.91 C5AR1 (0.41) C5AR1TSHRLMNACRHR1ATP4A
SCHEMBL651956 0.91 C5AR1 (0.43) C5AR1TSHRLMNAATP4AATP4B
SCHEMBL652505 0.90 C5AR1 (0.42) C5AR1TSHRLMNAATP4AATP4B
SCHEMBL5136974 0.89 ATP4A (0.39) C5AR1TSHRCRHR1ATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed